A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States
- PMID: 32209248
- DOI: 10.1016/j.vaccine.2020.03.017
A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States
Abstract
Background: MenACYW-TT is an investigational quadrivalent meningococcal conjugate vaccine intended for use in individuals ≥6 weeks of age. We evaluated the safety and immunogenicity of MenACYW-TT when compared to a licensed quadrivalent conjugate meningococcal vaccine (Menveo®; MCV4-CRM; GlaxoSmithKline, Italy), and when co-administered with tetanus, diphtheria, acellular pertussis (Tdap) and human papilloma virus (HPV4) vaccines in healthy meningococcal vaccine-naïve adolescents (10-17 years old) in the United States of America.
Methods: In this pivotal Phase II, open-label, multicenter study, 1715 participants were randomized to receive MenACYW-TT, MCV4-CRM, MenACYW-TT co-administered with Tdap and HPV4, or Tdap and HPV4 vaccines alone (NCT02199691). The primary objective was to evaluate whether antibody responses to MenACYW-TT antigens were non-inferior to antibody responses after MCV4-CRM administration. Meningococcal antibody titers were determined using human complement serum bactericidal assay (hSBA) with titers measured at baseline, and 30 days post vaccination (D30). A vaccine seroresponse was defined as baseline titers <1:8 with post-vaccination titers ≥1:8 or baseline titers ≥1:8 with a ≥4-fold increase at post-vaccination. Safety data were collected up to six months post-vaccination.
Results: Non-inferiority was demonstrated for MenACYW-TT vs MCV4-CRM (primary endpoint), and for MenACYW-TT co-administered with Tdap and HPV4 vs MenACYW-TT alone (secondary endpoint). The vaccine seroresponse rate was higher with MenACYW-TT than with MCV4-CRM, for each serogroup: A: 75.6% vs 66.4%; C: 97.2% vs 72.6%; W: 86.2% vs 66.6%; Y: 97.0% vs 80.8%. The safety profiles of MenACYW-TT, MCV4-CRM, and Tdap and HPV4 vaccines, administered with or without MenACYW-TT, were comparable. There were no vaccine-related serious adverse events.
Conclusions: The MenACYW-TT vaccine was well tolerated and generated an immune response that was non-inferior to the licensed MCV4-CRM vaccine. Immunogenicity and safety profiles were comparable when MenACYW-TT was administered with or without Tdap and HPV4 vaccines in meningococcal vaccine-naïve adolescents.
Keywords: Concomitant vaccine; Conjugate vaccine; HPV4; Invasive meningococcal disease; MenACYW-TT; Meningococcal vaccine naïve adolescents; Tdap.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: LJC, JP, EJ, & MSD are employees of Sanofi Pasteur. JH and SC received a grant to carry out the research at their respective study sites.
Similar articles
-
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix in Healthy Adolescents: A Randomized Phase IIIb Multicenter Study.Infect Dis Ther. 2024 Aug;13(8):1835-1859. doi: 10.1007/s40121-024-01009-x. Epub 2024 Jul 2. Infect Dis Ther. 2024. PMID: 38955966 Free PMC article.
-
Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study.Pediatr Res. 2023 Sep;94(3):1035-1043. doi: 10.1038/s41390-023-02478-5. Epub 2023 Mar 10. Pediatr Res. 2023. PMID: 36899125 Free PMC article. Clinical Trial.
-
Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) in Meningococcal Vaccine-Naïve Participants across a Broad Age Range (2-55 Years) in Japan: a Phase III Randomized Study.Jpn J Infect Dis. 2023 May 24;76(3):174-182. doi: 10.7883/yoken.JJID.2022.272. Epub 2023 Jan 31. Jpn J Infect Dis. 2023. PMID: 36724939 Clinical Trial.
-
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT): A review of the evidence and expert opinion.Expert Rev Vaccines. 2023 Jan-Dec;22(1):447-456. doi: 10.1080/14760584.2023.2211162. Expert Rev Vaccines. 2023. PMID: 37144288 Review.
-
Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix™).Drugs. 2012 Dec 24;72(18):2407-30. doi: 10.2165/11209580-000000000-00000. Drugs. 2012. PMID: 23231026 Review.
Cited by
-
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix in Healthy Adolescents: A Randomized Phase IIIb Multicenter Study.Infect Dis Ther. 2024 Aug;13(8):1835-1859. doi: 10.1007/s40121-024-01009-x. Epub 2024 Jul 2. Infect Dis Ther. 2024. PMID: 38955966 Free PMC article.
-
Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older.Infect Dis Ther. 2023 Oct;12(10):2367-2386. doi: 10.1007/s40121-023-00864-4. Epub 2023 Sep 27. Infect Dis Ther. 2023. PMID: 37755671 Free PMC article.
-
Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study.Pediatr Res. 2023 Sep;94(3):1035-1043. doi: 10.1038/s41390-023-02478-5. Epub 2023 Mar 10. Pediatr Res. 2023. PMID: 36899125 Free PMC article. Clinical Trial.
-
Efficacy and Safety of Quadrivalent Conjugate Meningococcal Vaccines: A Systematic Review and Meta-Analysis.Vaccines (Basel). 2023 Jan 13;11(1):178. doi: 10.3390/vaccines11010178. Vaccines (Basel). 2023. PMID: 36680022 Free PMC article. Review.
-
Vaccination for meningococcal disease.Rev Bras Ginecol Obstet. 2022 Sep;44(9):901-906. doi: 10.1055/s-0042-1757755. Epub 2022 Oct 10. Rev Bras Ginecol Obstet. 2022. PMID: 36216269 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical